Moderna, Inc. Increase (Decrease) in Inventories
Moderna, Inc. (MRNA) reported Increase (Decrease) in Inventories of $126.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-07-31
- Moderna, Inc. increase (decrease) in inventories for the quarter ending 2026-06-30 was $132.00M, a 15.79% increase year-over-year.
- Moderna, Inc. increase (decrease) in inventories for the quarter ending 2026-03-31 was -$6.00M, a 175.00% decline year-over-year.
- Moderna, Inc. increase (decrease) in inventories for the quarter ending 2025-12-31 was -$179.00M.
- Moderna, Inc. increase (decrease) in inventories for the quarter ending 2025-09-30 was $91.00M, a 727.27% increase year-over-year.
- Moderna, Inc. increase (decrease) in inventories for fiscal 2025 was $34.00M.
- Moderna, Inc. increase (decrease) in inventories for fiscal 2024 was -$83.00M.
- Moderna, Inc. increase (decrease) in inventories for fiscal 2023 was -$747.00M.
- Moderna, Inc. increase (decrease) in inventories for fiscal 2022 was -$492.00M, a 135.29% decline from fiscal 2021.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month | Increase (Decrease) in Inventories 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $132.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $126.00M 10-Q · filed 2026-07-31 | -$53.00M derived: sum of 3 quarters · filed 2026-07-31 | $38.00M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2026-03-31 | -$6.00M 10-Q · filed 2026-05-01 | -$185.00M derived: sum of 2 quarters · filed 2026-05-01 | -$94.00M derived: sum of 3 quarters · filed 2026-05-01 | $20.00M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-12-31 | -$179.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$88.00M derived: sum of 2 quarters · filed 2026-02-20 | $26.00M derived: sum of 3 quarters · filed 2026-07-31 | $34.00M 10-K · filed 2026-02-20 | |
| 2025-09-30 | $91.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $205.00M derived: sum of 2 quarters · filed 2026-07-31 | $213.00M 10-Q · filed 2025-11-06 | -$78.00M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-06-30 | $114.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $122.00M 10-Q · filed 2026-07-31 | -$169.00M derived: sum of 3 quarters · filed 2026-07-31 | -$158.00M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-03-31 | $8.00M 10-Q · filed 2026-05-01 | -$283.00M derived: sum of 2 quarters · filed 2026-05-01 | -$272.00M derived: sum of 3 quarters · filed 2026-05-01 | -$168.00M derived: sum of 4 quarters · filed 2026-05-01 | |
| 2024-12-31 | -$291.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$280.00M derived: sum of 2 quarters · filed 2026-02-20 | -$176.00M derived: sum of 3 quarters · filed 2026-02-20 | -$83.00M 10-K · filed 2026-02-20 | |
| 2024-09-30 | $11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $115.00M derived: sum of 2 quarters · filed 2025-11-06 | $208.00M 10-Q · filed 2025-11-06 | -$77.00M derived: sum of 4 quarters · filed 2026-02-20 | |
| 2024-06-30 | $104.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $197.00M 10-Q · filed 2025-08-01 | -$88.00M derived: sum of 3 quarters · filed 2026-02-20 | -$316.00M derived: sum of 4 quarters · filed 2026-02-20 | |
| 2024-03-31 | $93.00M 10-Q · filed 2025-05-01 | -$192.00M derived: sum of 2 quarters · filed 2026-02-20 | -$420.00M derived: sum of 3 quarters · filed 2026-02-20 | -$438.00M derived: sum of 4 quarters · filed 2026-02-20 | |
| 2023-12-31 | -$285.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$513.00M derived: sum of 2 quarters · filed 2026-02-20 | -$531.00M derived: sum of 3 quarters · filed 2026-02-20 | -$747.00M 10-K · filed 2026-02-20 | |
| 2023-09-30 | -$228.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$246.00M derived: sum of 2 quarters · filed 2024-11-07 | -$462.00M 10-Q · filed 2024-11-07 | -$1.59B derived: sum of 4 quarters · filed 2025-02-21 | |
| 2023-06-30 | -$18.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$234.00M 10-Q · filed 2024-08-01 | -$1.36B derived: sum of 3 quarters · filed 2025-02-21 | -$1.21B derived: sum of 4 quarters · filed 2025-02-21 | |
| 2023-03-31 | -$216.00M 10-Q · filed 2024-05-02 | -$1.34B derived: sum of 2 quarters · filed 2025-02-21 | -$1.19B derived: sum of 3 quarters · filed 2025-02-21 | -$1.21B derived: sum of 4 quarters · filed 2025-02-21 | |
| 2022-12-31 | -$1.13B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$972.00M derived: sum of 2 quarters · filed 2025-02-21 | -$993.00M derived: sum of 3 quarters · filed 2025-02-21 | -$492.00M 10-K · filed 2025-02-21 | |
| 2022-09-30 | $156.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $135.00M derived: sum of 2 quarters · filed 2023-11-03 | $636.00M 10-Q · filed 2023-11-03 | $1.11B derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-06-30 | -$21.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $480.00M 10-Q · filed 2023-08-03 | $956.00M derived: sum of 3 quarters · filed 2024-02-23 | $1.28B derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-03-31 | $501.00M 10-Q · filed 2023-05-04 | $977.00M derived: sum of 2 quarters · filed 2024-02-23 | $1.30B derived: sum of 3 quarters · filed 2024-02-23 | $1.45B derived: sum of 4 quarters · filed 2024-02-23 | |
| 2021-12-31 | $476.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $798.00M derived: sum of 2 quarters · filed 2024-02-23 | $946.00M derived: sum of 3 quarters · filed 2024-02-23 | $1.39B 10-K · filed 2024-02-23 | |
| 2021-09-30 | $322.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $470.00M derived: sum of 2 quarters · filed 2022-11-03 | $918.00M 10-Q · filed 2022-11-03 | $965.00M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-06-30 | $148.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $596.00M 10-Q · filed 2022-08-03 | $643.00M derived: sum of 3 quarters · filed 2023-02-24 | $643.00M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-03-31 | $448.00M 10-Q · filed 2022-05-04 | $495.00M derived: sum of 2 quarters · filed 2023-02-24 | $495.00M derived: sum of 3 quarters · filed 2023-02-24 | $495.00M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2020-12-31 | $47.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $47.00M derived: sum of 2 quarters · filed 2023-02-24 | $47.00M derived: sum of 3 quarters · filed 2023-02-24 | $47.00M 10-K · filed 2023-02-24 | $46.53M 10-K · filed 2021-02-26 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |